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With advances in refractive surgery and demand for cataract removal and lens replacement, the ocular use of nonsteroidal anti-
inﬂammatory drugs (NSAIDs) has increased. One of the most commonly used NSAIDs is diclofenac (Diclo). In this study,
cyclodextrins (CDs), α-, β-, γ-, and HP-β-CDs, were investigated with in vitro irritation and in vivo ulceration models in rabbits
to reduce Diclo toxicity. Diclo-, α-, β-, γ-, and HP-β-CD inclusion complexes were prepared and characterized and Diclo-CD
complexes were evaluated for corneal permeation, red blood cell (RBCs) haemolysis, corneal opacity/permeability, and toxicity.
Guest- (Diclo-) host (CD) solid inclusion complexes were formed only with β-, γ-, and HP-β-CDs. Amphipathic properties for
Diclo were recorded and this surfactant-like functionality might contribute to the unwanted eﬀects of Diclo on the surface of the
eye. Contact angle and spreading coeﬃcients were used to assess Diclo-CDs in solution. Reduction of ocular toxicity 3-fold
to16-fold and comparable corneal permeability to free Diclo were recorded only with Diclo-γ-CD and Diclo-HP-β-CD
complexes. These two complexes showed faster healing rates without scar formation compared with exposure to the Diclo
solution and to untreated groups. This study also highlighted that Diclo-γ-CD and Diclo-HP-β-CD demonstrated fast healing
without scar formation.
1. Introduction
Cyclodextrins (CDs) are cyclic oligosaccharides with a
hydrocarbon (water repellant) cavity and a hydrophilic outer
surface composed of 6, 7, or 8 dextrose units forming the
three parent cyclodextrins α-, β-, and γ-CDs. Depending on
the number of dextrose units, the hydrophobic cavity varies
in size and can accommodate various lipophilic moieties
and form guest-host complexes. These complexes have been
well-known as inclusion complexes and utilized in pharmacy
and cosmetic industries to enhance water solubility and bio-
availability of poorly soluble drugs and to improve palatabil-
ity by reducing the bitterness of certain drugs [1, 2]. More
recently, CDs have been employed to fabricate drug-loaded
textiles for treatment of surface skin diseases due to psoriasis,
fungal infections, and insect bites [3].
CDs have gained much popularity and are widely used in
the pharmaceutical industry for systemic routes such as oral
and parenteral dosage forms [4]. Orally administered CDs
are considered to be nontoxic because of their lack of absorp-
tion from the gastrointestinal tract and γ- and hydroxypro-
pyl- (HP-) β-CD having been used safely via the parenteral
route [5]. It is well-known that faster onset of action and less
gastrointestinal side eﬀects are attributed to oral piroxi-
cam-β-CD than piroxicam alone [4]. In addition, Dyloject®
and Akis® are two relatively new commercially available
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injectable Diclo-HP-β-CD complexes that gave rapid and
eﬀective analgesia comparable to Voltaren® IM injection
not containing CDs [4].
The use of CDs in ophthalmology has been recently
reported for solubilization of insoluble drugs such as cortico-
steroids [6], medications for treating glaucoma [7] and
immunosuppressive agents [8] and for enhancing ocular per-
meability of drugs through the extremely lipophilic corneal
epithelial membrane [9]. For example, CDs have been more
successfully used to solubilize dorzolamide at physiological
pH and to oﬀer comparable ocular bioavailability at low vis-
cosity (3 to 5 centipoises), to that found with high viscosity
(100 centipoises) eye drops as well as at low pH of 5.65 to sol-
ubilize 2% of dorzolamide [7]. However, the use of eye drops
containing α-CD> 4% has been found to cause superﬁcial
epithelial toxicity and microerosion in rabbit corneal tissue
[10]. These eﬀects most likely result from the ability of CD,
especially α- and β-CD, to extract cholesterol and other lipid
components from cell membranes [11] leading to cellular
disruption and enhanced drug permeation through the cor-
neal epithelial membrane [9]. Conversely, γ- and hydroxy-
propyl-β-CD are better tolerated in ocular tissues and less
likely to cause disruption of the corneal epithelial barrier
[8, 9]. CDs have the potential to alter drug availability at
the absorption site as well as to modify the rate of drug
release and hence can be applied to reduce drug irritation
caused by localized high concentrations. There are no
reports of research that has critically assessed the ocular irri-
tation potential from drug-CD complexes versus free drug
solutions using in vitro irritation models.
With the advent of modern refractive and cataract sur-
geries, nonsteroidal anti-inﬂammatory drugs (NSAIDs) have
been increasingly used in ophthalmology as a safer alterna-
tive to topical corticosteroids, avoiding serious side eﬀects
such as increasing IOP, cataractogenesis, risk of infection,
and stromal melting [12]. NSAIDs can eﬀectively reduce
miosis, inﬂammation, pain, and scleritis and, more impor-
tantly, prevent and treat cystoid macular oedema associated
with cataract surgeries [13, 14]. Diclofenac eye drops (0.1%
w/v) and other NSAIDs such as ketorolac tromethamine
(0.5% w/v), suprofen (1% w/v), ﬂurbiprofen (0.03% w/v),
and indomethacin (1%) are commercially available and
widely used for multiple indications such as reducing pain
and inﬂammation after ocular surgery and for seasonal aller-
gic conjunctivitis [14]. Side eﬀects and toxicities that have
been widely reported with topical application of NSAIDs
can range from transient burning, stinging, and conjunctival
hyperaemia to more serious eﬀects such as superﬁcial kerati-
tis, corneal erosion, corneal epithelial defect, and corneal
ulceration and melting [12, 15, 16].
This study aimed to investigate a possible role of CDs for
reducing local irritation and corneal toxicity of the most
widely used NSAID, namely, diclofenac. Previous studies
have sought to investigate corneal irritation potential from
Voltaren Ophtha eye drops and cyclodextrins such as
hydroxypropyl-β-CD using in vitro models such as hen’s
egg test-chorioallantoic membrane (HET-CAM), cytotoxic-
ity, and haemolysis assay [17, 18]. Both in vitro and in vivo
assessments for ocular irritation potential of Diclo with four
diﬀerent CDs, employing bovine corneal opacity and perme-
ability (BCOP), RBC haemolysis and MTT assay using
human primary corneal epithelial cells, and in vivo corneal
healing in rabbits have been undertaken in this study. No
reported investigations to date have considered the amphi-
pathic properties of Diclo that are assessed in this work for
surface tension and contact angle measurements using drop
shape analysis.
2. Materials and Methods
2.1. Materials. Diclofenac sodium was donated by PSM
Healthcare Pharma, Auckland, New Zealand. α-, β-, γ-,
and HP-β-CD, cellophane membrane (MW-cut oﬀ
12,000-14,000 Dalton), nitro blue tetrazolium (NBT), and
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) were purchased from Sigma-Aldrich, UK. All
other chemicals and reagents were of analytical grade and
used as received.
2.2. Preparation of Diclo-CD Physical Mixtures. Equivalent
amounts in mg of 1 : 1 molar ratios of Diclo and diﬀerent
types of CD (α-, β-, γ-, and HP-β-CD) were separately
weighed and mixed uniformly in a porcelain dish with a
spatula for 5 minutes. The physical mixtures were collected
in glass vials and sealed and stored in a cool dry place for
further use.
2.3. Preparation of Diclo-CD Complexes Using Solvent
Evaporation Method. Diclo and diﬀerent types of CD (α-,
β-, γ-, and HP-β-CD) were weighed in 1 : 1 molar ratios
and dissolved separately in methanol (20ml) and deionized
water (10ml), respectively. The two solutions were mixed
and magnetically stirred in 100ml capacity-evaporating
basins and allowed to completely evaporate at 60°C. The
resulting solid complexes were left overnight in a desiccator
for removal of residual moisture and pulverized and stored
in glass vials for subsequent use.
2.4. Characterization of the Prepared Cyclodextrin Complexes
2.4.1. Diﬀerential Scanning Calorimetry. Diclo-, α-, β-, γ-,
and HP-β-CD and corresponding physical mixtures and
complexes (amounts of 5 to 8mg) were weighed separately
in an aluminum pan; an aluminum lid was replaced and
crimped using a pan press (Thermal Science, USA). The
temperature of the pan was gradually raised from 25 to
300°C at a rate of 10°C/min using a diﬀerential scanning cal-
orimeter (DSC) (Mettler Toledo DSC 822e0, Switzerland).
Nitrogen gas was purged at a rate of 45ml/min. Data were
collected online using Mettler STARe software version
8.10, Switzerland.
2.4.2. Fourier Transform Infrared Spectroscopy (FT-IR).
Amounts (2–4mg) of Diclo-, α-, β-, γ-, and HP-β-CD and
the physical mixtures and complexes were used to form a
thin ﬁlm covering a diamond window of the FT-IR spec-
trometer (Thermo Scientiﬁc Nicolet iS5, Thermo ﬁsher,
Madison, USA). The data were collected and analyzed using
Omnic software (Omnic version 8.2, USA). The FT-IR
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spectra were registered at a spectral resolution of 2 cm−1 with
an average of 20 scans and a scanning range of 4000 cm−1 to
600 cm−1.
2.4.3. Molecular Docking. In order to predict the orientation
within the cavity and/or rim and gain more insights into
the stability/binding constants of Diclo with α-CD, β-CD,
γ-CD, and HP-β-CD, molecular docking studies were per-
formed using Molecular Operating Environment (MOE)
2014.09 software (Chemical Computing Group, Montreal,
QC, Canada). The crystal structures of CDs were extracted
from Protein Data Bank (PDB): α-CD (PDB code: 5E6Y),
β-CD (PDB code: 5E6Z), and γ-CD (PDB code: 5E70)
[19]. Since no crystal structure is available for HP-β-CD,
the crystal structure of β-CD (PDB code: 5E6Z) was used
as a template to build the 3D structure of HP-β-CD
by substituting four primary hydroxyl groups with 2-
hydroxypropyl radical, as described elsewhere [20]. The
3D crystal structure of Diclo was retrieved from crystallo-
graphic data available in the Cambridge structural data-
base (Ref. Code: LIQFUN) [21]. The docking simulations
were performed using the induced ﬁt docking protocol.
All other parameters were used with the default molecular
operating environment (MOE) settings. The resulting
docking poses were visually inspected, and the best energy
pose for each type of the four Diclo-CD complexes
was selected.
2.5. Preparation of Diclo Solution (0.1% w/v) and Its
Equivalent from Diclo-CD Complexes. An amount of Diclo
(10mg) or equivalent to 10mg from the prepared Diclo-CD
complexes was dissolved in 10ml of isotonic solution of
phosphate buﬀer saline (PBS) pH7.4 and sterile ﬁltered
through 0.22μm sterile syringe ﬁlters to prepare ﬁnal solu-
tions containing 0.1% w/v of Diclo. The prepared solutions
were stored at 4°C until further use.
2.6. Evaluation of Diclo and Diclo-CD Solutions
2.6.1. Contact Angle, Surface Tension, and Spreading
Coeﬃcient Measurements. The contact angle and surface ten-
sion for Diclo (0.1% w/v) and its equivalent from Diclo-CD
solutions in PBS were performed according to our previously
published work using a drop shape analyzer (goniometer)
(Kruss Drop Shape Analysis, Hamburg, Germany) [22].
2.6.2. Transcorneal Permeation Studies Using Excised Porcine
Eyes. Excised porcine eyes were collected from a local abattoir
(Jennings Butchery, Surbiton, UK). The cornea was dissected
as previously described [22]. Franz diﬀusion cells were
employed for ex vivo permeation, and the temperature was
maintained at 35°C± 0.5°C. The receptor chambers were
ﬁlled (12ml) with PBS, pH7.4. The medium was constantly
stirred using small magnetic bars. Volumes of 2ml of each
formulation were pipetted into the donor compartment
providing a surface area of 1.7 cm2. Samples of 1ml were
withdrawn at predetermined time points for up to 8 h and
replaced with the same volume of the medium without
drug. The samples were analyzed at λmax = 275nm using a
UV/visible spectrophotometer (Genway 7305, Hanwell,
London, UK). Negative controls (in PBS without the drug)
were placed on corneae and were withdrawn at the same
time points as test samples.
The permeability coeﬃcient (Papp, cm/s) was calculated
using [23]:
Papp =
ΔQ
Δt 3600 ACo
1
ΔQ/Δt is the permeability rate of Diclo across the
excised porcine cornea; Co is the initial Diclo concentra-
tion (μg/cm3); A is the exposed surface area of the cornea
(cm2). The value of 3600 represents the conversion of hours
to seconds.
2.6.3. Red Blood Cell (RBC) Haemolysis Assay. The RBC assay
was based on DB-ALM protocol number 99 [24]. Fresh
bovine blood samples were collected from ABP Guildford
London, UK, and were mixed in a ratio of 1 in 10 with citrate
buﬀer as anticoagulate. The citrated blood was further
diluted to 4 : 10 volumes in PBS and then centrifuged at
1500×g, 4°C for 10 minutes. The supernatant was carefully
discarded, and the pellets were washed with sterile PBS. A
total of ﬁve washes were made. The ﬁnal pellets were resus-
pended in PBS supplemented with 10mmol/l glucose and
stored in the fridge until further use. The test materials
(Diclo-, α-, β-, γ-, and HP-β-CD and Diclo-, α-, β-, γ-, and
HP-β-CD dispersed mixtures) were dissolved in PBS at the
following ﬁnal assay concentrations in mg/l (w/v): 1, 10,
100, 1000, and 10,000. One part of the RBC ﬁnal suspension
was added to 3 parts of the test material in PBS to give the
aforementioned ﬁnal assay concentrations. The mixtures
were incubated for 60 minutes with agitation at room tem-
perature. After incubation, the samples were centrifuged at
1500×g and 4°C for 1 minute and the extent of haemolysis
was determined spectrophotometrically at 541nm using a
UV/visible spectrophotometer (Genway 7305, Hanwell,
London, UK) and the percentage haemolysis estimated by
comparison with a sample that was totally lysed with deion-
ized water. The concentration of a test substance that induced
the lysis of 50% of RBCs (H50%) was determined and used to
evaluate the irritation potential of Diclo-CD mixtures.
2.6.4. Bovine Corneal Opacity and Permeability (BCOP)
Assay. Bovine eyes were obtained from a local slaughterhouse
(ABP Guilford, London, UK). Eyes with corneal damage or
abnormalities were discarded. Three diﬀerent controls were
used for validation purposes; sodium hydroxide (0.5M) was
used as a corrosive test substance, benzalkonium chloride
(BKC) 1% w/v in PBS was used as a strong irritant control,
and propylene glycol as a slight irritant. Diclo solution
(0.1% w/v) and Diclo-CD solutions containing an amount
equivalent to 0.1% w/v of Diclo were tested.
The extent of corneal damage was assessed by evaluating
the opacity, followed by application of sodium ﬂuorescein
solution (2% w/v pH7.4) to examine the integrity of the cor-
neal epithelium, using an examination lamp and a cobalt blue
ﬁlter (Leica, GmbH, Germany). Individual numerical scores
for opacity, epithelial integrity (degree of staining), and epi-
thelial detachment were reported elsewhere [25] and in more
3Oxidative Medicine and Cellular Longevity
recently published work [26]. The sum score was estimated
and the mean score for each of the three eyes was used to
interpret the corneal irritation potential.
2.6.5. Cytotoxicity Evaluation (MTT Assay). Primary human
corneal epithelial cells (ATCC pcs-700-010) from ATCC
were seeded at approximately 2× 104 cells/well into 96 well
plates (Nunc, Netherland) using corneal epithelial cell basal
medium containing apotransferrin (5mg/ml), epinephrine
(1.0mM) extract P (0.4%), hydrocortisone hemisuccinate
(100 ng/ml), L-glutamine (6mM), rh insulin (5mg/ml), and
CE growth factor (1ml). The cells were allowed to establish
for 48 hours prior to treatment. Media were removed and
fresh media containing 5 diﬀerent treatments were added.
The treatments were Diclo (0.1% w/v) and Diclo-, α-, β-,γ-,
and HP-β-CD solutions containing equivalent concentra-
tions of Diclo 0.1% w/v. The medium served as the negative
control and benzalkonium chloride (BKC) at a concentration
of 0.01%w/vwas used as the positive control. After 4 hours of
treatment, the media were removed and the cells were
washed twice with sterile PBS at 37°C and then further
incubated with 200 μl per well of 0.5mg/ml 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solu-
tion at 37°C. After incubation, the MTT solution was
carefully removed and the wells were washed twice with ster-
ile PBS. Finally, 200μl of dimethylsulfoxide (DMSO) was
added to each well to lyse the cells. The cells were then gently
agitated to mix the samples and analyzed on a TECAN Inﬁ-
nite M200 pro plate reader (Männedorf, Switzerland) at a
wavelength of 540nm. Experiments were performed in trip-
licate, and the average percentage cell viability was estimated.
2.6.6. In Vivo Study (Alcohol Delamination and Corneal
Epithelial Scrapping). Speciﬁed amounts of Diclo or equiva-
lent from Diclo-γ-CD- and HP-β-CD-dispersed mixtures
were dissolved in Vigamox® eye drops to form Diclo 0.1%
w/v solutions. Twenty-seven white albino rabbits, weighing
between 2.0 and 2.5 kg, were used in the experiments. The
rabbits were fed on balanced diet pellets and maintained on
12 h/12 h light/dark cycle in an air-conditioned room, at
28°C before the experiment. The experimental procedures
were approved by Minia University Animal Ethics Commit-
tee (Minia, Egypt) and conformed to ethical guidelines.
The rabbits were divided into three groups with nine
animals in each. Table 1 summarizes the diﬀerent types
of treatment. Each treatment was initiated directly after
induction of the corneal ulcer as a single drop instilled
every 6 hours.
Prior to induction of ulcers, both eyes were locally anaes-
thetized with instillation of a single drop of Benox® eye
drops (0.4% benoxinate hydrochloride) in each eye. A
6mm ring was applied to the central corneal zone, and
20% v/v ethyl alcohol was applied inside the ring for 15 sec-
onds to ease epithelial removal (delamination) followed by
epithelial scrapping with a sterile scalpel blade. The ulcers
were immediately stained with ﬂuorescein, and the stain
was visualized in a dark room using a hand-held indirect
ophthalmoscope with a cobalt blue ﬁlter (Omega 500, Heine,
Germany); the treatment was initiated as aforementioned.
2.6.7. Statistical Analysis. Statistical analysis was performed
with GraphPad Prism 6 (2014) software, using analysis of
variance (ANOVA) with a Dunnett post hoc test for conﬁ-
dence intervals of 95% with statistical signiﬁcance set at p <
0 05 in order to reveal statistical signiﬁcant diﬀerences
among contact angle, surface tension, spreading coeﬃcient,
transcorneal permeation parameters, cumulative BCOP
scores, and % cell viability.
3. Results and Discussion
3.1. Diﬀerential Scanning Colorimetry.DSCwas used to study
the crystallinity of Diclo and the possibility of formation of
Diclo-CD inclusion complexes. Figures 1(a)‑1(d) shows the
thermal behavior of Diclo with diﬀerent types of CDs (α-,
β-, γ-, and HP-β-CD), respectively. Diclo demonstrates a
strong thermal endothermic event at 290°C caused by melt-
ing of diclofenac sodium. This strong melting peak was
reduced in intensity with α-CD PM and complexes, and it
completely disappeared with β-, γ-, and HP-β-CDs. The
complete disappearance of the drug peak with CDs strongly
suggests molecular dispersion and formation of molecular
inclusion complexes of Diclo with β-, γ-, and HP-β-CDs.
Shifting of the melting peak to the lower end of the tempera-
ture scale and formation of a lower intensity melting peak
may indicate the formation of partial/incomplete inclusion
complexes of Diclo with α-CD and could be caused by poorer
ﬁtting of the relatively bulky diclofenac within the smallest
cavity size of 6-sugar units α-CD, compared with the higher
7- and 8-sugar units β- and HP-β-CDs, and γ-CD, respec-
tively. The DSC curves of the physical mixtures and the
dispersed mixtures that were prepared by the solvent evapo-
ration technique did not show any marked diﬀerences
because the heat supply during the DSC procedure can pro-
vide suﬃcient power equivalent to that of the solvent evapo-
ration, which brings drug molecules and CD into intimate
molecular dispersion/complexation. Similar behavior with
other water-soluble carriers has been reported [27].
3.2. FT-IR Spectroscopy. FT-IR spectroscopy was utilized to
study any potential interactions between Diclo and diﬀerent
CDs, as shown in Figures 2(a)‑2(d). The IR spectrum of Diclo
Table 1: Summary of the rabbit groups recruited in the study and their treatments.
Group Left eye Right eye
Group 1
Vigamox eye drops
Vigamox eye drops containing 0.1% w/v Diclo
Group 2 Vigamox eye drops containing Diclo-γ-CD equivalent to 0.1% w/v Diclo
Group 3 Vigamox® eye drops containing Diclo-HP-β-CD equivalent to 0.1% w/v Diclo
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showed a strong characteristic peak at 1600 cm−1 assigned for
C=O, two IR absorption peaks resulting from secondary
amine N-H, and aromatic stretching C =C-bands at 3400
and 3300 cm−1 [28]. These spectral regions are of interest
for investigating the possibility of formation of inclusion
complexes [29]. All CDs that showed a characteristic broad
stretching absorption peak appearing at 3550 to 3200 cm−1
were assigned to diﬀerent alcoholic O-H of the cyclic sugar
Diclo
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Figure 1: DSC curves for (a) Diclo, α-CD, α-CD-Diclo (PM), and dispersed (CPX); (b) Diclo, β-CD, β-CD-Diclo (PM), and dispersed
(CPX); (c) Diclo, γ-CD, γ-CD-Diclo (PM), and dispersed (CPX); and (d) Diclo, HP-β-CD, and HP-β-CD physical (PM) and dispersed
(CPX) mixtures.
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units of α-, β-, γ-, and HP-β-CDs (Figures 2(a)-2(d)). The
physical mixtures (PM) were a superimposition of the two
spectra of Diclo and corresponding CDs when their charac-
teristic peaks were unchanged; this occurred with Diclo-α,
β-, γ-, and HP-β-CD PM. Apart from Diclo-α-CD, signiﬁ-
cant changes in the IR region of 3550–3200 cm−1 were seen
with Diclo-, β-, γ-, and HP-β-CD-dispersed mixtures
prepared by the solvent evaporation method. Additionally,
the strong absorption bands of C=O group of Diclo were
markedly reduced in intensity and showed a frequency shift
with all CDs. These changes can be explained by characteris-
tic guest-host interactions and formation of inclusion
complexes of Diclo with β-, γ-, and HP-β-CD-dispersed
mixtures. Conversely, Diclo- and α-CD complex still shows
a small peak at 3300, which might be indicating the free drug,
as well as incomplete complexation for α-CD. These results
concurred with those obtained using DSC.
3.3. Molecular Docking. To gain more insights into the bind-
ing mode and binding constants between Diclo and individ-
ual CDs, molecular docking between Diclo and α-, β-, γ-, and
HP-β-CDs was performed. Molecular docking simulation is
the best method to predict drug (guest) orientations, molec-
ular ﬁtting and interactions into/onto the host (CDs) hydro-
phobic cavity, and hydrophilic rims at the molecular level
[30]. Figure 3 summarizes the molecular docking results.
The binding constants estimated for Diclo-, α-, β-, γ-, and
HP-β-CDs complexes were −4.3 kcal/mol, −4.4 kcal/mol,
−4.8 kcal/mol, and −5.2 kcal/mol, and the force of binding
of Diclo with CDs was in the following order: HP-β-
CD>>γ-CD>β-CD>α-CD.
Electrostatic interactions (H-bonding) between carboxyl-
ate group of Diclo and the hydrophilic rim (hydroxyl groups:
OH) of α-CD Figure 3, ia and ic) were recorded. However,
the size of the α-CD cavity was too small to host the dichlor-
ophenyl ring of Diclo (the dichlorophenyl ring was
completely outside the CD cavity) (Figures 1(a) and 2(a)).
This led to a less stable complex with a binding constant of
−4.3 kcal/mol. These results correlated well with DSC and
FT-IR studies (Figures 1(a) and 2(a)) where the Diclo melting
peak appeared with the processed Diclo- and α-CD mixture
indicating a negligible physicochemical interaction. Con-
versely, both γ- and HP-β-CDs had suitable cavity sizes for
hosting Diclo in their hydrophobic cavity (Figure 3, ic, iic,
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Figure 2: FT-IR spectra for (a) Diclo, α-CD, α-CD-Diclo (PM), and dispersed (CPX); (b) Diclo, β-CD, β-CD-Diclo (PM), and dispersed
(CPX); (c) Diclo, γ-CD, γ-CD-Diclo (PM), and dispersed (CPX); and (d) Diclo, HP-β-CD, and HP-β-CD physical (PM), and dispersed
(CPX) mixtures.
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iiic, id, iid, and iiid ) where the dichlorophenyl ring was
completely buried in γ- and HP-β-CDs. The cavity size of
HP-β-CDs is larger than that of α-CD, and it contains an
additional extension arising from the hydroxypropyl substi-
tution when compared with β-CD. The two hydrogen bonds
as well as the halogen-hydrogen bond could also contribute
to a very stable complex with binding energy of −5.2 kcal/
mol. The cavity size of γ-CD is suﬃciently large to host Diclo
with three hydrophobic interaction sites that lead to a stable
complex with binding energy of −4.8 kcal/mol (Figure 3, iiic).
While the β-CD cavity size is larger than that of α-CD,
the dichlorophenyl ring could not be entirely hosted within
it (Figure 3, iiib). Instead, the two aromatic rings of Diclo
were bent with a torsional angle of 69 degrees [31]; the
dichlorophenyl was partly outside the pocket/cavity as shown
in Figure 3, ib and Figure 3, iiib. This produces a fairly stable
complex with binding energy of −4.4 kcal/mol. Similar results
of the crystal structures of Diclo with β-CD have been
reported elsewhere [32].
3.4. Contact Angle, Surface Tension, and Spreading
Coeﬃcient. Table 2 shows the surface tension for Diclo solu-
tion (0.1% w/v in PBS) and equivalent amounts of Diclo-, α-,
β-, γ-, and HP-β-CD-dispersed mixtures that constitute the
Diclo solution of 0.1% w/v. The γ value recorded for Diclo
solution (0.1% w/v) was 52mN/m. This is a signiﬁcant
decrease in the surface tension of the Diclo solution com-
pared with the solvent (PBS) which was 76mN/m and sug-
gests that Diclo in solution has a surfactant-like property.
The dichloride substituted aromatic ring with the NH
linker to benzoate structure can explain the amphipathic
nature and surface active properties of diclofenac sodium.
(a)
(i)
(ii)
(iii)
(b) (c) (d)
Figure 3: The predicted orientations and binding interactions of diclofenac within the cavity of four cyclodextrins (a) α-CD, (b) β-CD,
(c) γ-CD, and (d) HP-β-CD from the top view of the wide edge (i), side view (ii), and as stick molecular depiction (iii). Hydrogen
bonds and hydrophobic interactions are demonstrated as magenta and green dashed lines, respectively.
Table 2: Contact angle, surface tension measurements, spreading, ﬂux, and apparent permeability coeﬃcient of diclofenac sodium from
solution and cyclodextrin complexes. Results presented as mean values± SD, n = 3. ∗ denotes statistically signiﬁcant diﬀerences (p < 0 05).
Formulation Contact angle (θ) Surface tension (mN/m) Spreading coeﬃcient Steady-state ﬂux (μg/h) Papp× 10−6 (cm/s)
Diclo 34± 0.65∗ 52.0± 2.5∗ −8.9± 2.00∗ 53± 1.5∗ 12.0± 0.5∗
Diclo-α-CD 52± 0.55 65.5± 1.0 −25.2± 1.0 21± 0.7 5.0± 0.5
Diclo-β-CD 50± 0.45 61.5± 2.0 −22.0± 1.5 19± 2.8 4.3± 1.0
Diclo-γ-CD 52± 0.80 60.35± 2.8 −23.2± 1.5 41.5± 3.5 9.4± 2.0
Diclo-HP-β-CD 53± 0.55 61.33± 2.0 −24.4± 2.0 41± 4.5 9.3± 2.0
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Amphipathic properties have been reported with structurally
similar drugs such as chlorpromazine, diphenhydramine,
chlordiazepoxide, and chlorcyclizine [33].
While the exact mechanism of the onset of corneal melt-
ing remains unknown [12], the above-reported surface
active properties attributed to Diclo may provide some
insight into how the topical ocular administration of Diclo
produces irritant/toxic eﬀects. It could be caused by expo-
sure of the ocular surface to relatively high local concentra-
tions of a drug with surface active properties that can induce
emulsiﬁcation and/or a sloughing of the extremely lipophilic
corneal epithelium.
The surface tension of Diclo-, α-, β-, γ-, and HP-β-CD
solutions exhibited a signiﬁcant (p < 0 05) increase in the
surface tension values (60–65.5mN/m). Furthermore,
Diclo-CD solutions showed signiﬁcant increases in contact
angle (θ) and associated signiﬁcant decreases in spreading
coeﬃcients (S). This supports the formation of complexes
of Diclo with α-, β-, γ-, and HP-β-CDs in solution that
may result in reducing the surface active properties of the
drug because the hydrophobic part of Diclo is found within
the cavity of CDs. These results are consistent with the dock-
ing calculations: various H-bonding and hydrophobic inter-
actions of carboxylate group and/or dichlorophenyl ring of
Diclo with the hydrophilic rims and hydrophobic cavities of
CDs were recorded (Figure 3, ia, iia, iiia, ib, iib, iiib, ic, iic, iiic,
id, iid, and iiid ). Furthermore, the behavior of complexes of
Diclo with CDs in solutions was reported to be diﬀerent than
their behavior in the solid state (1 : 1 molar complexation)
[34, 35]. The two aromatic rings have been reported to be
involved 1 : 2 CD complexation. This could explain why the
contact angle and surface tension measurements for Diclo-,
α-, β-, γ-, and HP-β-CD solutions did not show statistically
signiﬁcant diﬀerences (p> 0.05).
3.5. Transcorneal Permeation Study. Porcine corneal perme-
ation proﬁles of Diclo from free drug solutions and diﬀerent
Diclo-, α-, β-, γ-, and HP-β-CD complexes are outlined in
Figure 4. Permeation parameters (steady-state ﬂux and
apparent permeability coeﬃcient (Papp)) of the diﬀerent
Diclo solutions tested are given in Table 2. Both steady-
state ﬂux and Papp values (19–41.5μg/h and 4–9 cm/s) for
Diclo permeated from diﬀerent Diclo-, α-, β-, γ-, and HP-
β-CD solutions showed signiﬁcant controlled/sustained per-
meation of Diclo from α-, β-, γ-, and HP-β-CD solutions
compared with those values estimated for free Diclo solu-
tion (53μg/h and 12 cm/s). Cyclodextrins are extremely
hydrophilic and cannot permeate through lipophilic corneal
barriers [1, 10] suggesting that Diclo molecules had to be
liberated from the guest-host complex in order to permeate
through the corneal barrier and that the Papp of Diclo
is dependent on the binding forces of the guest-host
complexes [18].
Diclo complex with β-cyclodextrin has been reported to
transfer with higher rate through the cornea compared to free
drug in the previous studies [36]. Valls et al. used a diﬀerent
device to study transcorneal permeation through rabbit’s
cornea. While the setup was developed in-house and to our
knowledge this device is not available commercially, this
setup can take into consideration tear dynamics (washings)
and other ocular pharmacokinetic parameters. It is worth
noting that Franz diﬀusion cells are a static in vitro perme-
ation model that cannot perfectly mimic in vivo tear/ocular
dynamics that represent a major factor for drug loss of topi-
cally administered eye drops on the surface of the eye. Other
positive features resulting in prolonging precorneal residence
and mucoadhesion cannot be taken into account while using
this model. Therefore, faster permeation rates from drug
solutions have consistently been reported with this model
compared with many other formulations [22, 37].
More pertinently, the results showed that not all CDs
used provided equally controlled Diclo permeation through
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excised porcine corneae. While Diclo-, α-, and β-CDs
showed the lowest permeation rate (Papp) with 2.4-fold and
2.8-fold decreases compared with free Diclo solution, Diclo-
, γ-, and HP-β-CD solutions showed markedly higher (Papp)
compared with the previous two CD congers. Both Diclo-, γ-,
and HP-β-CD recorded (Papp) 1.27-fold lower than free
Diclo solution. Paradoxically, despite the docking calcula-
tions, showing that Diclo-, γ-, and HP-β-CDs were the most
stable complexes; the drug transcorneal permeation from
Diclo-, γ-, and HP-β-CD complexes was slightly faster than
that from Diclo-, α-, and β-CD complexes. It may be that
with ex vivo permeation, the binding forces are not the only
factors that aﬀect permeation rates through the cornea.
3.6. RBC Haemolysis Assay. RBC assay is an in vitro test that
has been used widely for testing ocular irritation potential of
ophthalmic pharmaceutical and cosmetic ingredients and
surfactants [38, 39]. Acute cytotoxicity due to cell lysis, cor-
neal erosion, and deepithelisation is well correlated with hae-
molytic activity and RBC lysis of test substances. The RBC
assay has been reported to be correlated with the in vivo rab-
bit Draize test [10, 39]. Figure 5 shows the concentrations
(H50) of the test substance that showed an absorbance value
equivalent to 50% haemolysis of RBCs. The estimated H50%
for Diclo was 2500mg/l, which is equal to 2.5 times of the
drug concentration in commercial eye drops (0.1% w/v).
The γ- and HP-β-CDs recorded H50% at extremely high con-
centrations and can be considered as essentially nonirritant.
Nevertheless, the α- and β-CDs were deemed to cause
haemolysis at lower concentrations compared with γ- and
HP-β-CDs. These ﬁndings support previous results indicat-
ing that α- and β-CDs can extract cholesterol and other lipid
components of cell membranes thereby contributing to cell
lysis [10, 11, 40]. It is worth noting that inclusion of Diclo
into the cavities of the CDs by formation of guest-host
complexes may have masked the inherent RBC haemolysis
potential of Diclo. For example, H50% recorded for Diclo-,
α-, β-, γ-, and HP-β-CDs ranged from 7000 to 40,000mg/l
compared with a much lower H50% value (2500mg/l) for
Diclo alone. This was accompanied by a reduction of cell lysis
and possible corneal erosion by 3 to 16 times, compared with
using the free drug alone.
3.7. BCOP Assay. The use of BCOP assay has been validated
and approved by the Scientiﬁc Advisory Committee of the
EuropeanCentre for theValidationofAlternatives (ECVAM).
The BCOP assay is widely used across the cosmetic and phar-
maceutical industries to test the ocular irritation potential of
surfactants, pharmaceutical ingredients, and ﬁnished prod-
ucts [41–43]. The BCOP assay uses the assessment of corneal
opacity and ﬂuorescence intensity as an indication of degree
of the disruption of the corneal barrier after exposure to the
test material (Figure 6).
Figure 7 shows the cumulative BCOP scores of corneal
opacity and epithelial integrity recorded for corrosive, strong,
and mild irritant control and test substance Diclo solution
Opacity of a corrosive
substance (NaOH 0.5 M)
Loss of lustre and epithelium
with a corrosive substance
(NaOH 0.5 M)
Conuent and intense uorescein stain
with a strong irritant
(BKC 1% w/v)
Weak stain with a mild irritant
(PG)
Opacity of a strong irritant
(BKC 1% w/v)
Mild-to-opacity of a mild irritant
(PG)
Figure 6: Degree of corneal opacity (upper) and ﬂuorescein permeability (lower) used to score the test substances (corrosive (sodium
hydroxide 0.5M), strong irritant (benzalkonium chloride 1%), and mild irritant (propylene glycol) models).
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and Diclo-, α-, β-, γ-, HP-β-CD solutions. The cumulative
score for Diclo solution recorded 1.5 corresponding to
mild-to-moderate irritants whereas Diclo-, α-, β-, γ-, HP-β-
CD solutions recorded scores 0.5 to 1 corresponding to
none-to-mild irritants with Diclo-, γ-, and HP-β-CD solu-
tions exhibited the lowest cumulative scores. These results
accord with the results from the RBC haemolysis assays.
3.8. Cytotoxicity Evaluation (MTT Assay). Percentage (%)
corneal epithelial cell viability after a 4-hour exposure to var-
ious treatments is shown in Figure 8. BKC was used as a pos-
itive control and showed extremely low cell viability (13%)
and was deemed to be cytotoxic at the duration tested in this
study [44–46]. Diclo recorded corneal cell viability of 21%
indicating poor cell viability and these results concur with
the other two in vitro ocular toxicity models (BCOP and
RBC haemolysis assays) and support previous reports on
the harmful eﬀects of topical application of Diclo to the
corneal epithelium [13, 14]. The % cell viability estimated
for Diclo-, α-, β-, γ-, and HP-β-CDs that contained an
equivalent concentration of Diclo 0.1% w/v was signiﬁ-
cantly increased from 3-fold to 5-fold (p < 0 01) compared
with free Diclo alone. While there were slight decreases in
cell viability after exposure to Diclo-, α-, and β-CDs, these
were correlated with the previous results that showed α- and
β-CDs are less tolerated by the ocular surface, compared with
γ- and HP-β-CDs. The latter can be considered as practically
nonirritant and were able to mask the acute ocular toxicity of
free Diclo solution.
3.9. In Vivo Study. Induction of corneal epithelial debride-
ment by alcohol-assisted removal of corneal epithelium
was adopted in this study as clinically relevant to the type
of corneal wounds created with photorefractive keratectomy
[47, 48]. Figure 9 shows a range of ﬂuorescein stained
corneal ulcers and corneal healing over time. Both eyes in
group I showed complete healing in four days but with a
nebula/scar in the right eye that received Vigamox eye drops
with the anti-inﬂammatory drug Diclo 0.1% w/v (the nebula,
seen at 72 hours, is indicated by an arrow). Group II and
group III showed markedly faster healing rates; ﬁve rabbits
out of 9 demonstrated complete corneal healing in 2 days
without scar formation. These results can be ascribed to
the following possibilities:
(i) Diclo-CDs may have lower direct irritation potential
and lower toxicity by masking the inherent
surfactant-like characteristics of Diclo.
(ii) Subjecting the corneal ulcer to a transient high local
concentration of free Diclo solution was avoided
when Diclo was instilled as inclusion complexes with
γ- and HP-β-CDs.
(iii) Diclo-CDs may prolong precorneal residence time
and enhance ocular bioavailability, compared with
instillation of free Diclo eye drops. The literature
indicates that dorzolamide-CD eyes drops with low
viscosity (3 to 5 centipoises) exhibited comparable
bioavailability with commercially viscous (100 centi-
poises) dorzolamide eye drops (Trusopt®) [7].
4. Conclusions
Ocular toxicity due to Diclo has been well reported and
attributed solely to pharmacological factors such as inhibition
of cyclooxygenase and/or upregulation of metalloproteinase
matrix [17]. In this study, we report for the ﬁrst time the pos-
sible toxicity of Diclo due to surfactant-like functionality and
a formulation approach to signiﬁcantly reduce/mask these
undesirable characteristics using CD inclusion complexation.
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Diclo and β-, γ-, and HP-β-CDs can form guest-host inclu-
sion complexes with diﬀerent capacities for permeating
through porcine corneae. The α- and β-CDs were deemed
to be less eﬀective at reducing the ocular unwanted toxicities
of Diclo resulting from inherent ability to extract cholesterol
and lipid components from the lipophilic corneal cell
membranes. Contact angles, surface tensions, and spreading
coeﬃcients, measured for the ﬁrst time, conﬁrmed guest-
host complex formation in solutions for the amphipathic
drug Diclo. In vitro toxicity model RBC haemolysis and
BCOP assays indicated the irritation potential from CD for-
mulations, and the results were well correlated with those
from the MTT cytotoxicity assay. The γ- and HP-β-CDs
oﬀer potential as carriers for eﬀectively diminishing Diclo
ocular toxicities. These two CD complexes exhibited a
marked reduction in RBC haemolysis and signiﬁcant
increase in cell viability compared with Diclo solution
alone. Diclo-γ- and Diclo-HP-β-CDs greatly enhance cor-
neal wound closure without scar formation, compared with
delayed corneal wound repair and scar formation with
Diclo solution alone.
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